PharmaShots Weekly Snapshot (May 06-10, 2019)
1.AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease
Published: May 10, 2019 | Tags: AstraZeneca, Reports, Results, Roxadustat, Global, Phase III, Programme, Cardiovascular Safety, Chronic Kidney Disease
2.Boston Scientific to Acquire Vertiflex for its Superion Indirect Decompression System
Published: May 10, 2019 | Tags: Boston Scientific, Acquire, Vertiflex, Superion Indirect Decompression System
3.Takeda Reports FDAs Acceptance of BLA for Entyvio (Vedolizumab SC) as a Maintenance Therapy in Moderate to Severe Active Ulcerative Colitis
Published: May 10, 2019 | Tags: US FDA, Accepts, Takeda, BLA, Entyvio, Vedolizumab, SC, Maintenance Therapy, Moderate, Severe, Active, Ulcerative Colitis
4.Medtronic To Acquire Titan Spine for its Portfolio of Implants and nanoLock Surface Technology
Published: May 10, 2019 | Tags: Medtroni, Acquire, Titan Spine, Portfolio, Implants, nanoLock Surface Technology
5.BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Published: May 10, 2019 | Tags: Boston Scientific,Acquire, Vertiflex, Superion Indirect Decompression System
6.Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist
Published: May 10, 2019 | Tags: Takeda, Signs, Licensing, Agreement, Curadev, Stimulator, Interferon Genes (STING) Agonist
7.Ethicon Acquires Rights of Takedas TachoSil Fibrin Sealant Patch for ~$400M
Published: May 10, 2019 | Tags: ~$400M, Acquires, Ethicon, Rights, TachoSil Fibrin Sealant Patch, Takeda
8. Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders
Published: May 09, 2019 | Tags: Collaborates, Commercialize, Develop, Gilead, Goldfinch Bio, Kidney Disorders, Therapies
9.Janssen (J&J) Expands its PTG-200 Collaboration with Protagonist for Second Generation Oral IL-23 Receptor Antagonists
Published: May 08, 2019 | Tags: Collaboration, Expands, IL-23, Janssen, Oral, Protagonist, PTG-200, Receptor, Antagonists, Second Generation
10. Medtronic Reports Results of MiniMed 640G System in the SMILE Study for Reducing Hypoglycemia in Patients with Type 1 Diabetes
Published: May 08, 2019 | Tags: Hypoglycemia, Medtronic, MiniMed 640G System, Reducing, reports, results, SMILE study, Type 1Diabetes
11. Novartis Acquires Worldwide Rights of Takedas Xiidra (lifitegrast ophthalmic solution) for $5.3B
Published: May 09, 2019 | Tags: Acquires, lifitegrast ophthalmic solution, Novartis, Rights, Takeda, Worldwide, Xiidra
12.Pfizer to Acquire Therachon for the Expansion of its Rare Disease Portfolio
Published: May 08, 2019 | Tags: Acquire, Expansion, Pfizer, Rare disease, Therachon
13.FDA Issues an Alert on Medtronics Pacemaker or Cardiac Resynchronization Therapy Pacemaker for its Premature Battery Depletion
Published: May 08, 2019 | Tags: Alert, FDA, Issues, Medtronic, Pacemaker, Premature, Battery, Depletion
14.AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer
Published: May 08, 2019 | Tags: (DS-8201), AstraZeneca, Daiichi, DESTINY-Breast01, Refractory, HER2+ Metastatic Breast Cancer, P-II, Results, Trastuzumab, Deruxtecan
15. Sanofis Dupixent (dupilumab) Receives European Commission Approval for Severe Asthma with Type 2 Inflammation
Published: May 07, 2019 | Tags: Approval, Asthma, dupilumab, Dupixent, European Commission, Receives, Sanofi, Severe Type 2 Inflammation
16. Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis
Published: May 08, 2019 | Tags: Ocrelizumab, Ocrevus, P-III, Primary Progressive Multiple Sclerosis Relapsing, Reports, Results, Roche, Studies, Three
17.AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia
Published: May 08, 2019 | Tags: Acalabrutinib, ASCEND, AstraZeneca, Calquence, Chronic Lymphocytic Leukaemia, P-III, r/r, Reports, Results, Study
18.Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis
Published: May 07, 2019 | Tags: MS Progression, Discussion, Tool, Multiple Sclerosis, Novartis, Patients, Reports, Results, Study, Validation
19.Takeda Collaborates with Skyhawk Therapeutics to Develop RNA Splicing Modifiers for Neurodegenerative Diseases
Published: May 06, 2019 | Tags: Collaborates, Develop, Modifiers, Neurodegenerative Diseases, RNA, Skyhawk Therapeutics, Splicing, Takeda
20.BioMarins Palynziq (pegvaliase injection) Receives European Commissions MAA Approval for Phenylketonuria
Published: May 06, 2019 | Tags: Approval, BioMarin, European Commission, MAA, Palynziq, pegvaliase injection, Phenylketonuria, Receives
21.Roche Reports Results of Risdiplam in FIREFISH and SUNFISH Studies for Spinal Muscular Atrophy
Published: May 07, 2019 | Tags: FIREFISH, Reports, Results, Risdiplam, Roche, Studies, SUNFISH
22.Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine
Published: May 06, 2019 | Tags: (galcanezumab-gnlm) Eli Lilly Emgality Episodic Migraine Frequency High Low P-III reports results Studies Treat
23. Pfizers Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) Receive FDAs Approval for Transthyretin Amyloid Cardiomyopathy
Published: May 06, 2019 | Tags: Approval, FDA Pfizer Receive Tafamidis tafamidis meglumine Vyndamax Vyndaqel
24. Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men
Published: May 06, 2019 | Tags: Astellas, Men, Mirabegron, Overactive Bladder, Symptoms, P-IV, PLUS, Reduce
25.Lundbeck to Acquire Abide Therapeutics for $400M
Published: May 06, 2019 | Tags: Abide Therapeutics, Acquires, Lundbeck, $400M
26.Roches Kadcyla (trastuzumab emtansine) Receives FDAs Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US
Published: May 06, 2019 | Tags: (trastuzumab emtansine), Adjuvant, Approval, Early, Breast Cancer, Expanded, FDA, HER2, Kadcyla, Receives, Roche, Treatment, US